
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Click the title above to open the Pharmaceutical Technology November 2013 issue in an interactive PDF format.
about 13 years ago
Report from Brazil November 2013about 13 years ago
Applying Catalysis to Optimize API Synthesisabout 13 years ago
Predicting Long-Term Storage Stability of Therapeutic Proteinsabout 13 years ago
Control of Elemental Impuritiesabout 13 years ago
Automation System Improves Operational Insightabout 13 years ago
Disposable Applications in Demand by Biopharmaabout 13 years ago
Solvent-Free Coating of Traditional and User-Friendly Dosage Formsabout 13 years ago
Congress Revises Rules for Drug Compounding and Supply-Chain Securityabout 13 years ago
Can Pharma Defy Gravity at the Patent Cliff?about 13 years ago
Defining and Presenting Overkill Cycle Validation




